515 results about "Senescence" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention relates to compositions (e.g., pharmaceutical compositions), uses, methods, non-therapeutic and therapeutic methods related to senolytic agents encapsulated or comprised in Muse cell derived extracellular vesicles (e.g. exosomes). Such compositions and methods are useful for specifically killing senescent cells and reverting any symptoms, disorders or diseases associated with senescence.

The invention discloses a ginseng extract rich in rare saponins and preparation and anti-aging application thereof, and belongs to the technical field of oral beauty and skin care products, the ginseng extract is obtained by fermentation treatment of ginseng powder through phytobacterium plantarum, and the preservation number of the phytobacterium plantarum is GDMCC No.64374. The ginseng extract rich in rare saponin is fermented by specific plant lactobacillus, ginsenoside is efficiently converted into CK and F1, various natural plant components such as ginseng polysaccharide are reserved, and a specific synergistic effect is generated. Through verification, the prepared ginseng extract is high in bioavailability, can more effectively inhibit cell inflammation, and can more effectively recover the mitochondrial function of senescent cells and inhibit cell senescence. The preparation method provided by the invention is high in operability and easy to standardize and intellectualize. Compared with a traditional extraction and purification method, the adopted fermentation method is more environmentally friendly and efficient, and large-scale production can be achieved in industrial production.

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

To provide senolytic agents to eliminate senescent cells and methods for treating diseases and disorders associated with senescence.SOLUTION: Disclosed is a method for removing senescent cells from banked stem cells, the method comprising adding to the stem cells at least one senolytic agent. Also provided is a pharmaceutical composition comprising at least one senolytic agent for use in a method for treating a disease, disorder or condition associated with senescence in a subject, where the method comprises removing stem cells from the subject, culturing the cells with the pharmaceutical composition, and administering to the subject the cultured cells.SELECTED DRAWING: None

The invention discloses a gene RhNADP-LIKE for regulating and controlling Chinese rose flower aging, and particularly relates to the technical field of molecular biology and horticultural plant physiology. According to the invention, bottle insertion life phenotype data of 358 parts of core germplasm of tetraploid Chinese rose is screened through genome-wide association analysis (GWAS), and the gene RhNADP-LIKE significantly associated with senescence is identified. The gene accelerates the aging process of petals by regulating the accumulation of reactive oxygen species (ROS). After RhNADP-LIKE expression is inhibited by using a virus-induced gene silencing (VIGS) technology, the blooming period of rosa chinensis flowers is prolonged by about 2 days, and the ROS level is remarkably reduced. The invention provides a molecular target for prolonging the vase life of the Chinese rose, can be applied to gene editing breeding or development of an environment-friendly preservative, reduces the dependence of chemical agents, and improves the economic benefit and sustainable development potential of the cut flower industry.

The invention belongs to the field of microorganisms, and particularly relates to application of lactobacillus paracasei L9 in preparation of a preparation for improving pulmonary fibrosis of an aged mouse. According to the lactobacillus paracasei L9 disclosed by the invention, the synthesis of I-type collagen is reduced by regulating and controlling gene expression, so that pulmonary fibrosis is relieved; meanwhile, the L9 improves the content of propionic acid and butyric acid in intestinal tracts and serum by regulating the abundance of SCFA-producing microbial flora in the intestinal tracts, so that pulmonary fibrosis is inhibited, and the L9 is a potential ideal preparation for improving or treating aging-related pulmonary fibrosis.

The invention discloses glycosylated ganoderic acid with a chemical structural formula shown in the specification, the compound can effectively improve H2O2-induced cellular morphological change, remarkably reduce generation of reactive oxygen species (ROS) and reduce accumulation of beta-galactosidase in senescent cells, and in addition, cell immunoblotting analysis shows that the compound can be used for preparing glycosylated ganoderic acid. The glycosylated ganoderic acid can significantly down-regulate the expression of H2O2-induced senescence marker proteins p16 and p21, and experimental results prove that the glycosylated ganoderic acid has potential in the aspect of reversing cell senescence, provides a new candidate compound for the development of anti-senescence drugs, and shows a wide application prospect; # imgabs0 #

The invention discloses an application of fangchinoline alkali in preparation of a product for inducing aging of tumor cells. The invention provides a novel application of fangchinoline alkali in induction of tumor cell senescence, which is beneficial to deep understanding of biological behaviors of tumor cells. By using the fangchinoline alkali as the tumor cell aging inducer, the aging process and the biological mechanism of tumor cells can be effectively simulated in an in-vitro or in-vivo model, so that a powerful tool is provided for biological research.

The invention discloses a senescent cell recognition system and method based on mitochondrial morphology. The system is a classification network, and the input data of the system is a distribution image of mitochondria in subcellular level cells, the distribution image of mitochondria in cells, the shape and / or number of mitochondria distributed at different positions in a three-dimensional structure for displaying cells, and preferably the shape and number of mitochondria distributed at different positions in the three-dimensional structure for displaying cells. According to the senescence cell recognition system based on the mitochondrial morphology, the senescence cells jointly show mitochondrial morphological changes including mitochondrial distribution, mitochondrial shapes and mitochondrial number changes, the senescence cell recognition method is easy to conduct through computer vision, good robustness is achieved, and the senescence cell recognition system based on the mitochondrial morphology is suitable for being applied to senescence cell recognition. Compared with other senescence cell identification methods based on cell nucleus morphological characteristics, the senescence cell identification method based on the general characteristics of the senescence cells has good universality for different cell types.

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention discloses a traditional Chinese medicine composition for repairing and / or activating residual ovarian functions of an aging ovary, and a preparation method and application thereof, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: radix astragali, radix angelicae sinensis, radix ophiopogonis, radix polygonati officinalis, semen cuscutae, radix morindae officinalis, fructus rubi, rhizoma dioscoreae and folium mori. The invention further provides application of the traditional Chinese medicine composition in repairing and / or activating the residual ovarian function of the senescent ovary and improving the quality of the senescent oocyte, the traditional Chinese medicine composition can increase the volume and weight of the senescent ovary, increase the number of follicles of all levels in the senescent ovary, reduce apoptosis of granular cells in the ovary and improve the survival rate of the senescent ovary. The abnormal rate of oocytes, oxidative stress of the oocytes and DNA damage are reduced, development and maturation of residual follicles are promoted and maintained, and the traditional Chinese medicine composition has a wide application prospect.

The invention discloses a nerve cell senescence resisting medicine containing p-hydroxybenzaldehyde and application thereof.The p-hydroxybenzaldehyde is adopted as the only active substance, and the p-hydroxybenzaldehyde can reduce accumulation of DNA damage in cells, reduce activity of beta-galactosidase in the cells and slow down reduction of cell metabolic capacity, so that the nerve cell senescence resisting medicine is obtained. Therefore, the senescence of nerve cells is effectively slowed down, the cognitive function is improved, and a potential treatment effect is achieved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The invention discloses lactobacillus crispatus for relieving senescence by promoting collagen synthesis and a metagen of the lactobacillus crispatus, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 metagen provided by the invention has a good skin anti-aging effect, the content of collagen is increased, meanwhile, the skin moisture can be increased, and the skin oxidation resistance can be improved. Specifically, the enzyme activity of MMP-3 and MMP-1 of HSF cells can be inhibited in vitro by thallus lysate, and the content of COL I and COL III and the enzyme activity of LH1 can be improved in vitro from fermentation of supernate; the enzyme activity of MMP-1 and MMP-3 can be inhibited by orally taking inactivated thalli; the self-fermented supernate is orally taken, so that the enzyme activity of LH1 and LOX can be improved, the enzyme activity of MMP-3 can be reduced, and the anabolism of collagen can be regulated and controlled.

The invention discloses a circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and a preparation method and application of the circRNA nano delivery system. The circRNA nano delivery system comprises: a) Klotho circRNA, and b) a liposome, and the liposome comprises a vascular peptide vasculotide, an ionizable lipid molecule, a phospholipid, a PEG lipid, and a steroid. The invention also provides application of the circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence in preparation of drugs for treating intervertebral disc degeneration. The invention provides liposome particles (Vas-Klotho-LNP) which have targeted NPPCs and wrap circRNA, Klotho circRNA is efficiently introduced into the NPPCs through Tie2 agonist peptide, so that rejuvenation of the NPPCs is promoted, ECM synthesis is promoted, and regeneration and repair of intervertebral discs are synergistically promoted in vivo and in vitro.

The invention relates to an in-vitro model of skin inflammatory aging as well as an establishment method and application thereof, and relates to the technical field of cell models. The model comprises human fibroblasts and an aging inductor of the fibroblasts, and the aging inductor is a culture medium supernatant of human keratinocytes with inflammation. According to the method disclosed by the invention, the inflammatory culture medium of the keratinocytes is used for inducing the senescence of the fibroblasts, so that the correlation between senescence characteristics of the human keratinocytes and the fibroblasts in an inflammatory environment is more truly reflected, and the key biological process of skin inflammatory senescence is more accurately reflected; the application of the cell model in a real living body environment and the accuracy of disease mechanism research are improved.

The invention discloses a galactose-masked aminoquinoline compound and application thereof, the structural formula of the galactose-masked aminoquinoline compound is # imgabs0, and R is acetyl, propionyl or butyryl. After being subjected to hydrolysis deacetylation, propionylation or butyrylation by esterase in cells, the compound can be activated by senescence-related beta galactosidase in senescence cell lysosome to release aminoquinoline (NCQ) so as to inhibit the survival of senescence cells in vivo or in vitro.

The invention belongs to the technical field of biology, and discloses a fusion type polypeptide for improving the activity of umbilical cord mesenchymal stem cells and application of the fusion type polypeptide. The amino acid sequence of the fusion type polypeptide provided by the invention is any one sequence as shown in SEQ ID NO.1-3. The fusion type polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The umbilical cord mesenchymal stem cells obtained by culturing the fusion type polypeptide have good multiplication capacity, can promote expression of the Ki67 gene and inhibit aging of the umbilical cord mesenchymal stem cells, and have wide application prospects.

A composition capable of preventing or improving skin aging by controlling a senescence biomarker of melanocytes is disclosed. The composition includes a thymol ester-based compound as an effective ingredient, whereby when applied to a subject in which skin cells are flattened or enlarged, or β-galactosidase of melanocytes is activated, it can exhibit the effect of preventing or improving skin aging.

Provided herein are nucleic acid inhibitors or activators that impact the expression, levels or activity of SNORA13 in a cell. Also provided are pharmaceutical compositions for using these activators and inhibitors for the treatment of ribosomopathies, cancer, and senescence-associated pathologies.

The invention provides application of arabian jasmine flower lactone in preparation of a medicine for resisting senescence caused by microgravity. The arabian jasmine flower lactone can inhibit dissolution and / or deconstruction of F-actin caused by microgravity, stabilize cytoskeleton, and further inhibit or delay the aging process under microgravity. The invention also provides application of the arabian jasmine flower lactone in preparation of medicines for preventing and / or treating space diseases. The arabian jasmine flower lactone can inhibit organ and / or cell function decline caused by weightlessness in a space environment.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses an anti-aging and anti-fatigue traditional Chinese medicine formula and a preparation method thereof. The traditional Chinese medicine formula comprises the following raw materials in parts by weight: 10-12 parts of ginseng, 10-15 parts of rhodiola rosea, 8-10 parts of dendrobium officinale, 5-6 parts of turmeric, 5-8 parts of cordyceps militaris, 8-10 parts of radix puerariae, 6-10 parts of schisandra chinensis, 1-3 parts of liquorice, 8-10 parts of lycium ruthenicum, 8-10 parts of cistanche, 10-12 parts of acanthopanax and 8-10 parts of phellinus igniarius. The adaptive capacity of an organism to an anoxic environment is improved, fatigue is effectively relieved, and various active ingredients contained in the health-care food contribute to delaying the senescence process.

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of bone marrow mesenchymal stem cells and application of the recombinant polypeptide. The amino acid sequence of the recombinant polypeptide is as shown in SEQ ID NO.3. The recombinant polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The recombinant polypeptide provided by the invention can promote the expression of the Ki67 gene and improve the proliferative activity of the bone marrow mesenchymal stem cells, also has the effect of inhibiting the replicative aging of the bone marrow mesenchymal stem cells, and has a wide application prospect.

The invention relates to the technical field of biology, in particular to an engineered vesicle carrying mRNA targeting and application of the engineered vesicle to improvement of fibroblast functionality. The iRGD polypeptide carried by the engineered vesicle is used as a targeting polypeptide of fibroblasts, specifically targets human dermal fibroblasts and can be combined with rich integrin alpha v and NRP-1 on cell membranes of the fibroblasts, meanwhile, the iRGD polypeptide and exosome surface mask protein emp2b construct a fusion protein, MS2 capsid protein is fused in exosome, and the human dermal fibroblasts can be specifically targeted to the human dermal fibroblasts. According to the present invention, with the combination of the mRNA containing the MS2 stem loop, the more target mRNA can be obtained, such that the more target mRNA can enter the senescent fibroblast in the targeting manner so as to improve the activity of the fibroblast and delay the senescence of the human skin;

The invention discloses a Bifidobacterium bifidum CCFM1424 capable of relieving senescence and an application of the Bifidobacterium bifidum CCFM1424, and belongs to the technical field of microorganisms. The bifidobacterium bifidum CCFM1424 disclosed by the invention can be used for effectively relieving cognitive defects of aged mice, improving the oxidation resistance (SOD, CAT, MDA and GSH-Px) of the brain and the liver, reducing the levels of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum and relieving colitis. In addition, the intervention of the bifidobacterium bifidum CCFM1424 can maintain muscle health, and can improve the change of intestinal flora and intestinal metabolites related to aging. According to the bifidobacterium bifidum, the application range of the bifidobacterium bifidum as probiotics is expanded, and the bifidobacterium bifidum has a huge application prospect in the aspect of relieving senescence.